Preeclampsia: A Marker for Future Cardiovascular Risk in Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01519297|
Recruitment Status : Recruiting
First Posted : January 26, 2012
Last Update Posted : January 23, 2018
This study will compare blood vessel and hormone differences between women who have a history of a pregnancy complicated by preeclampsia or high blood pressure, and women who have a history of uncomplicated pregnancy in the last 10 years. The investigators hypothesize that postpartum women with history of preeclampsia will have altered blood vessel function and abnormal hormone levels compared with postpartum women with history of uncomplicated pregnancy.
This study will take place over the course of 2 weeks. Each subject will be assessed on a fixed low-salt diet and a fixed high-salt diet. Subjects will have 2 non-invasive blood vessel imaging tests and fasting blood draws.
|Condition or disease||Intervention/treatment||Phase|
|Preeclampsia Pregnancy Induced Hypertension||Drug: Irbesartan||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Preeclampsia: A Marker for Future Cardiovascular Risk in Women|
|Study Start Date :||May 2012|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||June 2018|
Single arm intervention
Irbesartan 150 mg orally for one dose
150mg orally for one dose
- Vascular function [ Time Frame: 60 minutes ]Assess vascular function after administration of an angiotensin receptor blocker.
- Hormonal measurements [ Time Frame: 60 minutes ]Assess hormone levels pertaining to the renin-angiotensin system after administration of irbesartan.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01519297
|Contact: Ellen W Seely, MD||617-732-8538|
|United States, Massachusetts|
|Brigham and Women's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Ellen W Seely, MD||Brigham and Women's Hospital|